OneDigital Investment Advisors LLC Decreases Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

OneDigital Investment Advisors LLC cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 34.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,829 shares of the medical equipment provider's stock after selling 7,823 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Intuitive Surgical were worth $7,285,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Hazlett Burt & Watson Inc. lifted its position in shares of Intuitive Surgical by 5.8% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock worth $177,000 after purchasing an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc. raised its position in Intuitive Surgical by 4.1% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock worth $247,000 after buying an additional 20 shares during the last quarter. Ullmann Wealth Partners Group LLC lifted its stake in shares of Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock worth $653,000 after purchasing an additional 21 shares during the period. One Wealth Management Investment & Advisory Services LLC increased its position in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider's stock worth $310,000 after buying an additional 23 shares in the last quarter. Finally, Falcon Wealth Planning grew its position in shares of Intuitive Surgical by 0.4% during the third quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider's stock worth $2,797,000 after purchasing an additional 23 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on ISRG shares. Royal Bank of Canada upped their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the company an "outperform" rating in a research report on Friday, October 18th. Piper Sandler reiterated an "overweight" rating and set a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an "overweight" rating in a research note on Friday, October 18th. Citigroup boosted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday, August 22nd. Finally, Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus target price of $513.74.

Intuitive Surgical Stock Down 1.9 %

ISRG traded down $10.19 during trading on Friday, hitting $527.61. The company's stock had a trading volume of 1,447,836 shares, compared to its average volume of 1,461,285. The firm has a market capitalization of $187.92 billion, a P/E ratio of 85.96, a PEG ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $295.02 and a twelve month high of $544.38. The stock's fifty day moving average price is $498.17 and its 200-day moving average price is $456.22.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business's stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 93.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jamie Samath sold 22,903 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the sale, the insider now directly owns 8,757 shares of the company's stock, valued at approximately $4,597,425. The trade was a 72.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,178 shares of company stock valued at $45,897,071. Company insiders own 0.90% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.